Rapid Micro Biosystems, Inc. Class A (RPID)

RPID's stock price has been influenced by several events over the past six months. The company reported a 3% increase in total revenue for Q3 2025 and raised its full-year revenue guidance, leading to a positive stock reaction. Preliminary Q4 and full-year 2025 revenue showed increases of 37% and 20% year-over-year, respectively. A new $45 million term loan facility was announced, strengthening the company's financial position. A major shareholder, Longitude Capital Partners II, LLC, reduced its stake through stock sales. As of early February 2026, RPID's stock traded at $3.87, with a 1-year low of $1.86 and a 1-year high of $4.94.

Information on demand seasonality for Rapid Micro Biosystems' products and services is not explicitly available. However, the company's business model, which includes recurring consumables revenue and strong system placements, suggests a relatively stable and growing demand rather than significant seasonal fluctuations.

Rapid Micro Biosystems, Inc. (RPID) is a life sciences technology company specializing in automation solutions for healthcare product manufacturing. The company operates in the Life Sciences Technology sector, focusing on automating microbial quality control (MQC) testing workflows. Its main product, the Growth Direct® platform, delivers faster results, greater accuracy, and improved compliance. The company also offers RMBNucleus Mold Alarm software and related services.

Rapid Micro Biosystems has a global presence with operations in the United States, Germany, Switzerland, Japan, and internationally. Its U.S. manufacturing is based in Lowell, Massachusetts, with additional locations in Switzerland, Germany, and the Netherlands.

Rapid Micro Biosystems maintains a positive brand reputation, driven by market acceptance of its Growth Direct® system and consistent business execution. The company reported strong customer interest and operating trends, including a record multi-system customer order. Analyst sentiment is generally optimistic, with several "buy" ratings for the stock. No specific negative events impacting the company's brand reputation were prominently reported in the past year.

Rapid Micro Biosystems has a significant institutional ownership base, with 43 institutional owners holding a total of 14,935,442 shares. Major institutional owners include Bain Capital Life Sciences Investors, LLC, ABG-WTT Global Life Science Capital Partners GP Ltd, and Vanguard Group Inc. Insiders hold 29.96% of the company's stock and have sold more stock than they have bought in the past three months, with sales totaling $547,255.00.